

# Part Eight

Index



## A

- accountability (see external governance; internal governance)
- achievements (see also performance)
  - barcoding policy, 21
  - Blood Sector Data Strategy, 2, 22
  - Blood Suppliers Forum, 20
  - Comcover Award for Excellence in Risk Initiatives, 21
  - Factor VII and Factor IX Guidelines*, 20, 25
  - the first five years, 17–25
  - Fresh Blood Products: Production Benchmarking and Demand Drivers*, 20
  - Guidelines on the prophylactic use of RhD immunoglobulin (anti-D) in obstetrics*, 20
  - National Blood Data Workshop, 25
  - National IVlg Workshop, 24
  - National Safety and Quality in Healthcare Commission, 22, 28
  - National Supply Plan, 19, 24
  - NBA Fellows program, 21, 24
  - Prime Minister's Silver Award for Excellence in Public Sector Management, 21
  - Review of Distribution Arrangements for Blood Products, 17, 25, 85, 85
  - vCJD mitigation, 22
- Administrative Appeals Tribunal, 173
- advertising and market research, 114
- Archives Act 1983*, 173
- asset management, 114
- audit
  - external, 40
  - internal, 113
- Audit Committee
  - meetings, 39
  - membership, 38, 116
  - role, 39, 40
- Australasian Society of Blood Transfusion, 72, 77
- Australian and New Zealand Society of Blood Transfusion, 72
- Australian Antarctic Division, 82, 84
- Australian Bleeding Disorders Registry, 2, 20, 22, 23, 82, 83, 113
- Australian Commission on Safety and Quality in Health Care, 92
- Australian Customs Service, 82, 84
- Australian Defence Force, 82, 84
- Australian Haemophilia Centre Directors' Organisation, 83
- Australian Health Management Plan for Pandemic Influenza, 90
- Australian Health Ministers' Advisory Council
  - endorsements, 67, 88
  - role, 32, 33, 34, 57
- Australian Health Ministers' Conference
  - endorsements, budget, 45, 51
  - endorsements, other, 28, 29, 49, 50, 67, 79, 82, 85
  - role, 6, 32, 33, 34, 35, 46, 117, 173
  - submissions to, 21
- Australian Health Protection Committee, 13, 88, 89
- Australian Laboratory Services Pty Ltd, 31, 45, 46, 66
- Australian National Audit Office, 39
  - audit report, 124–125
  - Australian Public Service, 102
  - Australian Public Service Commission, 102
  - Australian Red Cross Blood Service
    - agreements to supply project, 56
    - annual capital plans, 51
    - annual funding commitments, 47
  - Australian Bleeding Disorders Registry, 83
  - barcoding policy, 86
  - business cases, 52, 53
  - business study, 7, 25, 49, 53
  - capital investment, 24, 51
  - change program, 53, 54
  - data collection, 76, 79
  - Deed of Agreement, 5, 25, 47, 49–53, 54
  - diagnostic reagents, use of, 66
  - funding, 47, 51, 53, 112
  - key performance indicators, 54
  - National Managed Fund (Blood and Blood Products) Special Account, 119
  - overseas supply of blood products, 84
  - performance, 53
  - Plasma Fractionation Review, 85
  - principal sites, 5, 7, 33, 49, 51
  - product mix, 47, 48
  - products supplied, 176
  - relationship with NBA, 4, 5, 7, 47, 51, 53, 78, 84
  - research and development, 50, 75
  - Review of Distribution Arrangements for Blood Products, 85
  - review of governance arrangements, 113
  - role as blood collector, 47
  - role as blood supplier, 31, 44
  - theme mapping, 50
  - third party reviews, 56
  - universal bacterial contamination testing, 79
- Australian Red Cross Society, 47, 119
- Australian Taxation Office, 122
- Australian Workplace Agreements, 99

## B

bacterial contamination testing, 20, 33, 49, 56, 79  
 barcoding, 21, 86  
 Baxter Healthcare Pty Ltd, 31, 44, 65, 177  
 biographies, Board members, 10–16  
 biographies, senior executive management, 36–38  
 blood and plasma products (see also blood supply)  
   bacterial contamination testing, 20, 33, 49, 56, 79  
   defined blood products, 65  
   diagnostic reagent products, 66  
   future trends, 106–110  
   imported products, 61–65, 82, 84  
   intravenous immunoglobulin, 60, 61  
   issues of all blood products, 80  
   issues of factor IX products, 63  
   issues of factor VIII products, 62  
   issues of intravenous immunoglobulin, 60  
   issues of IVIg products, 60  
   issues of platelets, 55  
   issues of recombinant factor VIIa products, 63  
   issues of red blood cells, 55  
   issues of total factor IX products, 64  
   issues of total factor VIII products, 64  
   leucodepletion, 20, 48, 49, 79  
   management of fresh blood products, 47–57  
   market share of diagnostic reagent supply, 66  
   market share of recombinant factor VIII products, 62  
   product change proposals, 57  
   product mix, platelets, 48  
   product mix, red blood cells, 48  
   production of fresh blood products, 47  
   production of plasma-derived products, 47, 59, 61  
   production of recombinant blood products, 61  
   review of distribution arrangements, 85  
   supplied by ARCBS, 175  
   supplied by Baxter Healthcare Pty Ltd, 177  
   supplied by CSL Ltd, 176, 177  
   supplied by Novo Nordisk Pharmaceuticals Pty Ltd, 177  
   supplied by Octapharma Australia Ltd, 176  
   supplied by Wyeth Australia Pty Ltd, 177  
 Blood Counts program, 67–69, 72–78  
   development of guidelines and standards, 67–68  
   education, information sharing and practice improvement initiatives, 74  
   improvements to systems, 74–75  
   research, data and benchmarking, 75–78  
   Review of NHMRC and Australasian Society of Blood Transfusion guidelines, 72–73  
 Blood Measures collaborative project, 78

blood supply  
   chain, 30–31  
   donors, 31  
   future trends, 106–110  
   government funding, 30  
   National Blood Supply Contingency Plan, 5, 20, 25, 33, 88, 89  
   NBA role, 30  
   suppliers, 31  
   Therapeutic Goods Administration, 30  
 blood transfusions  
   guidelines, 78  
   International Society for Blood Transfusion  
     annual conference, 2  
     pretransfusion testing, 66  
     professional societies, 72  
     Review of NHMRC and Australasian Society of Blood Transfusion guidelines, 72–73  
   safety, 2, 4, 74–77, 108  
 Board, National Blood Authority  
   Chair's report, 6–9  
   meetings, 24  
   members, 10–16  
 budget (see finance; financial statements)  
 Business Continuity Plan, 5, 94, 103  
 business study of Australian Red Cross Blood Service, 7, 25, 49, 53

## C

Chief Executive's Instructions, 40, 87, 113, 115  
 Clinical, Technical and Ethical Principal Committee, 32, 33, 34, 67, 88  
 Clinical Advisory Council, 19, 20, 21, 25, 67, 173  
 Clinical Excellence Commission (NSW), 77  
*Clinical Practice Guidelines on the Use of Blood Components*, 72  
 Comcover Award for Excellence in Risk Management, 5, 21, 25, 93, 94  
 Comcover Risk Management Benchmarking Survey, 93  
 Common Variable Immune Deficiency, 70  
 Commonwealth Disability Strategy, 103  
 Commonwealth Procurement Guidelines, 113, 115  
 competitive tendering and contracting, 114  
 consultancies, 115, 120  
 contracts  
   commercial contract management, 59–66  
   new, 4, 17, 19, 61, 65, 66, 115  
 Corporate Plan, 28, 91  
*Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia*  
   delivery, 17, 20, 67–68, 69, 95  
   endorsement, 2, 4, 33

## CSL Ltd

- contracts, 7, 17, 22, 31, 46, 61
- funding, 59
- imported IVIg products, 176
- imported plasma products, 177
- imported recombinant products, 177
- key performance indicators, 59
- market share, diagnostic reagents, 66
- national reserve of plasma products, 90
- Plasma Products Agreement, 176
- relationship with NBA, 24
- Review of Distribution Arrangements for Blood Products, 85
- role in supply chain, 31, 44, 47, 59
- visit by NBA Board, 6

## Customer Service Charter, 95

## D

## data management

- Australian Bleeding Disorders Registry, 82, 83
- Blood Measures collaborative project, 78
- corporate, 95
- Integrated Data Management System, 4, 87, 117
- sector information management and data strategy, 81

## Deed of Agreement, Australian Red Cross Blood Service, 5, 25, 47, 49–53, 54

## Department of Finance and Deregulation, 87, 120

## Department of Health and Ageing, 14, 36, 37, 72, 90

## DiaMed Australia Pty Ltd, 31, 45, 46, 66

## Disability Strategy, Commonwealth, 103

## discretionary grants, 113

## donors, 47

## deferral, 30, 108

## management, 52, 54, 89

## recruitment and retention, 49, 50, 53

## testing, 70, 79, 89, 106

## E

## e-learning, South Australian initiative, 74

## ecologically sustainable development, 91, 96

## ethics

## corporate, 100

## medical, 32, 33, 34, 67

## exempt contracts, 113

## expert advisory group, 49

## external audit, 40

## external governance, 32–34

## external scrutiny, 40

## F

## FEIBA (Factor VIII Inhibitor Bypass Agent), 44, 45, 80, 112

## finance, 117–122 (see also financial statements)

- administered expenses, 120
- administered items, 120
- administered liabilities, 122
- assets, 119–121
- expenses, 119
- funding, 117
- funding contributions from states and territories, 121
- key results, 112
- liabilities, 120
- operating result, 117
- performance overview, 117–119
- revenue, 119
- special accounts, 119
- summary resource table, 112

*Financial Management and Accountability Act 1997*, 87, 117, 119, 173

## financial statements, 124–172

## independent auditor's report, 124–125

## flood damage, NBA office, 25, 94, 119

## Food and Drug Administration (United States), 108, 110

## fraud

- fraud control activities, 96
- Fraud Control Plan, 40, 96

## freedom of information

- functions and powers of the NBA, 173
- procedures and contact details, 174
- statistics, 173

*Freedom of Information Act 1982*, 173, 174

## G

## General Manager

- review by, 2–5
- role, 35

## governance (see external governance; internal governance)

*Guide to the Preparation, Use and Quality Assurance of Blood Components*, 33, 49, 53

## H

## Haemophilia Foundation Australia, 12, 83

## Health and Ageing Portfolio Budget Statements, 41, 42

## Health Ministers, 33, 52, 67, 79, 80, 89 (see also

- Australian Health Ministers' Advisory Council;
- Australian Health Ministers' Conference)

## hma Blaze Pty Ltd, 114

## human immunodeficiency virus, 11, 77

## I

- Immune Deficiencies Foundation of Australia, 70, 71
- information and communications technology, 4, 81, 91, 94, 96
- information management (see data management)
- Initial Australian Haemovigilance Report*, 2, 17, 25, 74, 95
- insurance, flood damage compensation, 119
- Integrated Data Management System, 4, 87, 117
- internal governance, 35
- International Plasma Protein Congress, 8
- International Society for Blood Transfusion annual conference, 2
- intravenous immunoglobulin (IVIg) (see also *Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia*)
  - case study, 70–71
  - imported IVIg standing offer, 61
  - issues of, 60, 61
  - production, 61
  - top ten uses, 69

## J

- Jurisdictional Blood Committee
  - endorsements, 4, 8, 53, 61, 67, 68, 74, 86, 88
  - guidance, 67, 81
  - meetings, 24
  - role, 4, 7, 28, 33, 34, 51, 93
- Jurisdictional Direct Order, 61

## K

- key business processes, 39, 40, 92, 93, 113, 115
- key performance indicators
  - ARCBS, 53, 54, 56
  - CSL Ltd Plasma Products Agreement, 59, 59
  - imported recombinant blood product contract, 65, 65
  - National Blood Authority, 42, 43–46, 93
- knowledge management (see data management)
- KPMG Limited, 49, 53

## L

- letter of transmittal, iii
- leucodepletion
  - definition, 79
  - proportion of products leucodepleted, 48, 79
  - universal, 20, 49, 79

## M

- market research, 76, 77, 114
- Minister for Health and Ageing, 6, 21, 32, 33, 35
- Ministerial Council, 21, 23

## N

- National Blood Account, 119
- National Blood Agreement
  - establishment, 17, 29, 34
  - extract, 29
  - objectives, 28, 57, 67, 81, 106
  - provisions, 82, 84
  - responsibilities, 30, 32, 106, 117, 173
  - review, 9, 85
- National Blood Authority
  - capability strategy, 92
  - continuous improvement framework, 96
  - corporate performance, 91–96
  - corporate values, 100
  - customer service charter, 95
  - exempt contracts, 113
  - functions and powers, 173
  - history, 24–25, 29
  - internal governance, 35
  - occupational health and safety, 103
  - organisational structure, 35
  - performance pay, 99
  - productivity gains, 103
  - professional and personal development, 102
  - relationship with ARCBS, 4, 5, 7, 47, 51, 53, 78, 84
  - risk management, 6, 40, 93
  - role, 28, 173
  - salary levels, 99
  - staffing, 98–99
  - work culture and conditions, 100
  - workforce planning, 98–99
- National Blood Authority Act 2003*
  - blood sector governance arrangements, 32, 173
  - reporting and compliance requirements, 6, 117
  - requirements of NBA and Board, 6, 28, 29, 35, 93, 106
  - special accounts, 119
  - supply obligations, 19–23
- National Blood Supply Contingency Plan, 5, 20, 25, 33, 88, 89
- National Haemovigilance Project, 74
- National Health and Medical Research Council, 72, 73, 77
- National Indemnity Reference Group, 57
- National IVIg Management System, 4
- National Managed Fund, 20, 24, 35, 47, 57, 119

National Managed Fund (Blood and Blood Products) Special Account, 119  
 National Product List, 79  
 National Red Cell Utilisation Workshop, 75–77, 76  
 national reserve of plasma products, 90  
 National Supply Plan and Budget, 33, 45, 79, 87  
 New Zealand, 33, 75  
 Novo Nordisk Pharmaceuticals Pty Ltd, 31, 44, 65, 177

## O

occupational health and safety, 99, 103  
 Octapharma Australia Pty Ltd, 31, 46, 61, 176  
 Operational Plan, 8, 40, 91  
 organisational structure, 35  
 Ortho-Clinical Diagnostics, 31, 45, 46, 66  
 Outcome 1  
     key performance indicators, 42  
     total resources, 112  
 outputs (see achievements; performance)  
 outsourcing, 21, 113  
 overview, General Manager's, 2–5

## P

Parliamentary Secretary to the Minister for Health and Ageing, 6, 33  
 performance (see also achievements)  
     corporate performance, 91–96  
     improvements in price and product quality, 45  
     key performance indicators, 42–46, 93  
     management of Australia's blood supply, 43–45  
     national administered budget performance, 45–46  
 plasma fractionation, 8, 59  
 review of arrangements, 7, 85  
 Plasma Fractionation Review, 7, 85  
 plasma products (see blood and plasma products)  
 Plasma Products Agreement, 8, 22, 24, 59, 176  
 Portfolio Budget Statements, 41, 42  
 Professional and Community Forum, 20, 67, 173  
 Professional Development Scheme, 102  
*Public Service Act 1999*, 25, 95, 100, 117, 173  
 publications  
     *Clinical Practice Guidelines on the Use of Blood Components*, 72  
     *Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia*, 2, 4, 17, 20, 33, 42, 67–69, 95  
     *Factor VII and Factor IX Guidelines*, 20, 25  
     *Fresh Blood Products: Production Benchmarking and Demand Drivers*, 20

*Guide to the Preparation, Use and Quality Assurance of Blood Components*, 33, 49, 53  
*Guidelines on the prophylactic use of RhD immunoglobulin (anti-D) in obstetrics*, 20  
*Initial Australian Haemovigilance Report*, 2, 17, 25, 74, 95

## R

Review of Distribution Arrangements for Blood Products, 85  
 Review of New Technologies, New Techniques and New Products, 106, 107, 110  
 Review of NHMRC and Australasian Society of Blood Transfusion guidelines, 72–73  
 Review of the Australian Blood Banking and Plasma Product Sector, 29  
 risk management  
     Comcover award, 5, 21, 25, 93, 94  
     Strategic Risk Management Plan, 6, 40, 93

## S

secretariat services, 19, 34, 47, 57, 68, 93, 98  
 sector information management and data strategy, 81  
 senior executive management biographies, 36–38  
 Senior Executive Service, 99  
 supply (see blood supply)

## T

*Therapeutic Goods Act 1989*, 30  
 Therapeutic Goods Administration, 20, 30, 32, 53, 89, 102  
 transfusion-related acute lung injury, 108  
 transmittal letter, iii

## U

United States Food and Drug Administration, 108, 110

## V

variant Creutzfeldt-Jakob disease (vCJD), 22, 108

## W

Wyeth Australia Pty Ltd, 31, 44, 65, 177